Wilson's report made a couple of comments around previous...

Wilson's report made a couple of comments around previous management...


"The company’s previous commercialisation strategy relied upon third party distributors selling the product to surgeons. It appears this was characterised by lack of lack of proper training of both the distributor and then of course the surgeon. In addition, significant clinical trial data which is a key selling point for Key Opinion Leaders (KOLs) was lacking. A proper commercialisation strategy was clearly not in place"...

"As part of our research in preparing this report we spoke to a number of surgeons who have used or are using ReCell. To be fair it must be pointed out that many surgeons have not had successful outcomes with ReCell in the past. However, it is equally fair to point out that most surgeons have had no training on how to use ReCell. There are cases of surgeons who have not had positive outcomes, but after proper training have achieved successful outcomes."


read the comments of the surgeons in the report, its very insightful...
I'll put in seperate post.

and their last comment in Summary...


"ReCell has very broad market applications and unfortunately appears not to have been properly commercialised by previous management. The new management team has put in place a new strategy which we believe is showing success albeit off a very low base at this stage. The fact though that the US DoD is funding two final clinical trials in the US: for burns and scars, we believe bears testimony to the opportunity for the product."